Is Bio-Rad trying to replicate in 2005 the success it had in 1999 when it bought Sanofi Diagnostics Pasteur for $210 million?

With $200 million in credit lined up, Bio-Rad said it is very willing to spend almost half of it to acquire reagent company BioSource of Camarillo, Calif. Trouble is, BioSource is having none of it, and has rebuffed Bio-Rad at every turn.

Last week, Bio-Rad announced an $82-million proposal for BioSource, offering $8.50 a share for the publicly held reagent company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.